Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2012 1
2014 1
2019 1
2020 4
2021 3
2022 1
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Tursi A, Mocci G, Cingolani L, Savarino E, Pica R, Cocco A, Zippi M, Napolitano D, Schiavoni E, Pugliese D, Scaldaferri F, Costa F, Marzo M, Serio M, Scarcelli A, Bolognini L, Bendia E, Maconi G, Cannatelli R, Piergallini S, Bodini G, Calabrese F, Ferronato A, Pranzo G, Elisei W, Monterubbianesi R, Faggiani R, Rodinò S, Sebkova L, Grossi L, Gaiani F, Dè Angelis G, Lorenzetti R, Allegretta L, Cazzato AI, Scorza S, Della Valle N, Sacco R, Forti G, Colucci R, Tonti P, Neve V, Rocco G, Sacchi C, Zampaletta C, Pagnini C, Graziani MG, Di Paolo MC, Onidi FM, Usai Satta P, Picchio M, Papa A. Tursi A, et al. Among authors: di paolo mc. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1649-1656. doi: 10.1080/14656566.2023.2230126. Epub 2023 Jun 28. Expert Opin Pharmacother. 2023. PMID: 37358928
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, Scarcelli A, Pagnini C, Graziani MG, Di Paolo MC, Pranzo G, Luppino I, Paese P, Elisei W, Monterubbianesi R, Faggiani R, Ferronato A, Perini B, Savarino E, Onidi FM, Binaghi L, Usai Satta P, Schiavoni E, Napolitano D, Scaldaferri F, Pugliese D, Pica R, Cocco A, Zippi M, Rodino S, Sebkova L, Rocco G, Sacchi C, Zampaletta C, Gaiani F, De Angelis G, Kayali S, Fanigliulo L, Lorenzetti R, Allegretta L, Scorza S, Cuomo A, Donnarumma L, Della Valle N, Sacco R, Forti G, Antonelli E, Bassotti G, Iannelli C, Luzza F, Aragona G, Perazzo P, Lauria A, Piergallini S, Colucci R, Bianco MA, Meucci C, Giorgetti G, Clemente V, Fiorella S, Penna A, De Medici A, Picchio M, Papa A. Mocci G, et al. Among authors: di paolo mc. Expert Opin Biol Ther. 2023 Mar;23(3):293-304. doi: 10.1080/14712598.2023.2185510. Epub 2023 Mar 2. Expert Opin Biol Ther. 2023. PMID: 36843568
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A; IG‐IBD LIVE Study Group. Pugliese D, et al. Aliment Pharmacol Ther. 2022 Jul;56(1):95-109. doi: 10.1111/apt.16923. Epub 2022 May 12. Aliment Pharmacol Ther. 2022. PMID: 35876062 Free PMC article.
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients’ association representatives. Fiorino G, et al. Dig Liver Dis. 2019 May;51(5):632-639. doi: 10.1016/j.dld.2019.02.004. Epub 2019 Feb 19. Dig Liver Dis. 2019. PMID: 30872085 Review.
Probiotics in COVID-19 pandemic: when evidence lacks, rationale can still ease the way.
Pagnini C, DI Paolo MC, D'Alba L, Urgesi R, Pallotta L, Villotti G, D'Ambra G, Delle Fave G, Graziani MG. Pagnini C, et al. Among authors: di paolo mc. Minerva Gastroenterol (Torino). 2023 Jun;69(2):314-317. doi: 10.23736/S2724-5985.20.02760-9. Epub 2020 Sep 4. Minerva Gastroenterol (Torino). 2023. PMID: 32883053 No abstract available.
Fighting the Battle against SARS-CoV-2 as Gastroenterologists in Italy.
Pagnini C, Urgesi R, Di Paolo MC, Graziani MG. Pagnini C, et al. Among authors: di paolo mc. Gastroenterology. 2020 Oct;159(4):1619. doi: 10.1053/j.gastro.2020.03.067. Epub 2020 Apr 2. Gastroenterology. 2020. PMID: 32247691 Free PMC article. No abstract available.
17 results